Blockchain, basketball, Broadcast.com: Mark Cuban has never lost his passion for disruption. Now the billionaire entrepreneur has an ambitious plan to take on Big Pharma and lower the cost of prescription drugs once and for all. And, after 13 seasons, this savvy shark may finally be ready to leave the tank.
Cuban, the entrepreneur, has founded more than ten companies, starting in 1983 with software reseller MicroSolutions and up to Cost Plus Drugs, the public benefit corporation he started in January 2022, which aims to lower prescription drug prices. Cuban, the insta-billionaire, sold Broadcast.com, an internet sports radio outfit, to Yahoo for $5.7 billion at the peak of the dot-com bubble in 1999 (a few years later, Yahoo shuttered the service). Cuban, the investor, has poured at least $25 million into crypto concerns (including dogecoin, the currency famously started as a joke) and taken stakes in at least 400 startups, many through Shark Tank.
Mark Cuban sat down with Forbes reporter Jemima McEvoy to talk about Cost Plus Drugs, where he sees cryptocurrency going and what his biggest business regret is.
00:18 – What’s Most Important
02:26 – Cost Plus Drugs
10:02 – Cuban’s Changes To Capitalism
11:45 – Cuban on Cryptocurrency And Its Future Uses
19:11 – A Day In The Life Of Mark Cuban
21:10 – Cuban’s Favorite Venture To Date
22:18 – Cuban’s biggest career regret
23:19 – Biggest Influences
Read the full story on Forbes: https://www.forbes.com/sites/jemimamcevoy/2022/09/26/mark-cuban-considering-leaving-shark-tank—new-venture-focuses-on-selling-low-cost-drugs/?sh=6d409e3bcaa6
Subscribe to FORBES: https://www.youtube.com/user/Forbes?sub_confirmation=1
Forbes newsletters: https://newsletters.editorial.forbes.com
Forbes on Facebook: http://fb.com/forbes
Forbes Video on Twitter: http://www.twitter.com/forbes
Forbes Video on Instagram: http://instagram.com/forbes
More From Forbes: http://forbes.com
Forbes covers the intersection of entrepreneurship, wealth, technology, business and lifestyle with a focus on people and success.